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Abstract
Purpose of Review—Anti-neutrophil cytoplasmic autoantibodies (ANCA) are associated with
vasculitis. Current therapy involves administration of toxic therapy that is not optimally effective.
The review will summarize evidence for the pathogenicity of ANCA, which will suggest possible
strategies for improving treatment.
Recent Findings—Pauci-immune small vessel vasculitis is associated with antibodies against
myeloperoxidase (MPO-ANCA) and proteinase 3 (PR3-ANCA). One research group has reported
a high frequency of autoantibodies against lysosomal-associated membrane protein 2 (LAMP-2) in
patients with MPO-ANCA or PR3-ANCA. Epigenetic dysregulation appears to be the basis for
increased MPO and PR3 neutrophil gene expression in ANCA disease. Release of neutrophil
extracellular traps (NETS) may be involved in initiating the ANCA autoimmune response and
causing vessel injury. Generation of C5a by alternative pathway activation is involved in
pathogenesis in mouse models. Intervention strategies in mice that target antigens, antibodies and
inflammatory signaling pathways may translate into novel therapies. Animal models of LAMP-
ANCA and PR3-ANCA disease have been proposed. Molecular mimicry and responses to
complementary peptides may be initiating events for ANCA. T cells, including regulatory T cells,
have been implicated in the origin and modulation of the ANCA, as well as in the induction of
tissue injury.
Summary—Our basic understanding of the origins and pathogenesis of ANCA disease is
advancing. This deeper understanding already has spawned novel therapies that are being
investigated in clinical trials. This brief review shows that there are more questions than answers,
and new questions are emerging faster than existing questions are being answered.
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Introduction
Anti-neutrophil cytoplasmic autoantibodies (ANCA) are associated with a distinctive group
of necrotizing small vessel vasculitides that typically have a paucity of vascular deposition
of immunoglobulin and complement (1). This distinguishes ANCA disease from disease
caused by anti-glomerular basement membrane antibodies (anti-GBM disease) and classic
immune complex disease, both of which have conspicuous deposition of immunoglobulin in
vessel walls. However, even though pauci-immune ANCA disease does not have much
immunoglobulin in vessel walls, there is substantial evidence supporting a pathogenic role
for ANCA. Pauci-immune necrotizing and crescentic glomerulonephritis is a frequent
component of ANCA disease. The pathologic and immunohistologic features of
glomerulonephritis is indistinguishable in the different clinicopathologic variants of ANCA
disease, including Wegener’s granulomatosis (granulomatosis with polyangiitis),
microscopic polyangiitis, Churg-Strauss syndrome (allergic granulomatosis with
polyangiitis), or renal-limited pauci-immune necrotizing and crescentic glomerulonephritis.
Two major target antigens for ANCA are myeloperoxidase (MPO) and proteinase 3 (PR3),
which are proteins in the primary granules of neutrophils and the lysosomes of monocytes.
More recently, autoantibodies against human lysosomal-associated membrane protein 2
(LAMP-2) have been reported in patients with either MPO-ANCA or PR3-ANCA (2,3).
This review will summarize evidence that supports a pathogenic role for ANCA.
Clinical observations supporting pathogenicity of ANCA
Based solely on pathologic findings, in 1954 Godman and Churg proposed that Wegener's
granulomatosis, microscopic polyangiitis, and Churg Strauss syndrome might have a
common pathogenesis (4). The close association of circulating ANCA with these diseases
supports the relatedness of these clinicopathologic syndromes and suggests a common
pathogenesis. Additional clinical observations that support but do not prove a pathogenic
role for ANCA are the correlation of ANCA titers with response to treatment, the value of
anti-B cell therapy and plasma exchange in treatment (5,6), the induction of pauci-immune
small vessel vasculitis in patients who develop ANCA secondary to drug treatment (7,8),
and the correlation of ANCA disease with higher levels of ANCA target antigens on the
surface of circulating neutrophils (9,10). There also is one intriguing report of a neonate who
developed pulmonary and renal disease after transplacental passage of MPO-ANCA IgG
from a mother with microscopic polyangiitis (11). This raises the possibility that the infant
developed ANCA disease, however, no pathologic confirmation was obtained and no
additional corroborating cases have been reported.
In vitro observations supporting pathogenicity of ANCA
Many in vitro studies demonstrate mechanisms by which ANCA could cause vasculitis in
vivo (Figure 1). For example, incubation of ANCA IgG with neutrophils that have been
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primed with cytokines causes the release of destructive granule enzymes and toxic reactive
oxygen radicals (12). This increases the expression of ANCA antigens on the surface of
neutrophils where they can interact with ANCA to cause neutrophil activation (13). ANCA
activation of neutrophils is mediated by both engagement of Fc receptors by
immunoglobulin bound to MPO or PR3 (14,15) as well as by the binding of ANCA Fab’2 to
ANCA antigens on the surface of neutrophils (16,17). ANCA bind not only to ANCA
antigens at the surface of neutrophils and monocytes, but also to ANCA antigens adsorbed
onto endothelial cells and other tissue constituents at sites of injury (17). Leukocytes
activated by ANCA in vitro release mediators that are injurious to endothelial cells (18–20).
In vitro activation of neutrophils by ANCA also stimulates the release of neutrophil
extracellular traps (NETS) that contain chromatin and granule proteins including MPO and
PR3 (21,22). NETS also were observed in glomeruli from patients with glomerulonephritis
(21). NETS not only can trigger damage to endothelial cells, but may be involved in
initiating or perpetuating the ANCA autoimmune response by presenting ANCA antigens to
the immune system (21).
Recent studies have shed light on mechanisms by which ANCA antigens are displayed on
the surface of neutrophils. Abdgawad et al. observed a link between the increased membrane
expression of PR3 on neutrophils and expression of CD177 (NB1 glycoprotein) (23). Jerke
et al also observed the linkage of PR3 with CD177 and found evidence that this complex
interacts with the complement receptor Mac-1 to induce neutrophil activation (24). The
interaction of PR3 with associated molecules may play an important role not only in the
activation of neutrophils by PR3-ANCA, but also in the presentation of PR3 as an antigen to
the immune system (25).
As mentioned earlier, ANCA disease is associated with higher levels of ANCA target
antigens on the surface of circulating neutrophils (9,10). In addition, patients with ANCA
disease have aberrant transcription of PR3 and MPO genes in circulating neutrophils, which
normally is shut off before neutrophils are released from the bone marrow (26). Ciavatta et
al have discovered that this aberrant overexpression of genes for ANCA target antigens
(MPO and PR3) in ANCA disease patients is the result of disturbed epigenetic regulation
(27). An understanding of the expression and display of ANCA autoantigens may help
understand both the genesis of the autoimmune response and the pathogenic interaction with
ANCA, which could point to novel therapies.
Animal models of ANCA disease
Several animal models of ANCA disease have been described (28). Intravenous injection of
anti-MPO IgG into mice causes a pauci-immune necrotizing glomerulonephritis and a pauci-
immune systemic small vessel vasculitis that is pathologically identical to human ANCA
disease (29). Another mouse model has been produced by transplanting wild type (Mpo+/+)
bone marrow cells into irradiated MPO knockout (Mpo−/−) mice or vice versa (30). Bone
marrow-derived cells are sufficient and necessary for anti-MPO to cause glomerulonephritis
and vasculitis in this model because chimeric Mpo−/− mice with circulating MPO+/+
neutrophils develop glomerulonephritis, whereas chimeric Mpo+/+ mice with circulating
MPO−/− neutrophils do not (29). Disease in mouse models is enhanced by systemic
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administration of proinflammatory factors (31), ameliorated by anti-TNF-alpha (31), and
prevented by the depletion of neutrophils (32) or by inactivation of the alternative pathway
of complement activation (33,34, 35). In vitro, ANCA-activated neutrophils release factors
that activate complement (33,35). Activation of complement generates C5a, which is a
potent neutrophil chemoattractant and activator. Recent studies implicate the engagement of
C5a receptors as an important event in the induction of disease in these mouse models
(34,35).
These observations raise the possibility that therapy aimed at blocking complement
activation might be feasible in human ANCA disease. Two recent studies using mouse
models of MPO-ANCA disease suggest even more novel treatment strategies. Schreiber at al
found that phosphoinositol 3 kinase-gamma isoform (PI3Kgamma), which is required for a
number of signaling pathways involved in neutrophil activation, plays a pivotal role in
disease induced by anti-MPO in mice (36). PI3Kgamma deficient mice were protected
against disease induction, and a PI3Kgamma inhibitor prevented disease induction in vivo
and blocked activation of neutrophils by ANCA in vitro. Van Timmeren et al used a
different strategy to attenuate disease induction by anti-MPO IgG (37). They used a bacterial
endoglycosidase to treat the pathogenic anti-MPO IgG, which abrogates Fc receptor
engagement and complement activation by the IgG but does not interfere with antigen
binding. The hydrolyzed anti-MPO IgG was ineffective in vitro in activating neutrophils and
did not cause disease when injected into mice. These studies suggest that treatments that
modify either ANCA antibodies or effector neutrophils might be effective in ANCA disease.
A rat model of ANCA disease can be induced by immunizing rats with human MPO, which
induces anti-MPO antibodies that cross react with human and rat MPO (38). As in the
mouse model (31), anti-rat TNF antibodies ameliorate disease in this rat model (39). Of
interest with respect to these observations are recent clinical studies that suggest a role for
anti-TNF therapy in ANCA disease patients (40,41).
Although there are several credible animal models of MPO-ANCA disease, there has been
less success with producing a compelling model of PR3-ANCA disease, which has led some
to question the pathogenicity of anti-PR3 antibodies and to invoke other pathogenic
mechanisms for PR3-ANCA disease, such T cell mediated inflammation. Until recently, the
most promising model was described by Pfister at al who produced antibodies against
recombinant murine PR3 mice deficient in PR3 and elastase (42). Mice injected with these
anti-PR3 antibodies developed enhanced subcutaneous inflammation at sites injected with
tumor necrosis factor alpha, but did not develop glomerulonephritis or vasculitis. In 2009,
Primo et al. reported a more convincing model (43). They immunized autoimmunity prone
non-obese diabetic (NOD) mice with recombinant mouse PR3 in complete Freund's
adjuvant resulting in high levels of circulating anti-PR3. No disease developed, however,
when splenocytes from these immunized mice were transferred into immune deficient NOD-
severe combined immunodeficiency (SCID) mice, the mice developed necrotizing
glomerulonephritis and vasculitis. Control mice that received splenocytes from non-
immunized mice developed no disease, supporting a specific effect caused by PR3
immunization. This is a promising model, but additional studies are required to confirm and
elucidate the mechanism underlying the glomerulonephritis and vasculitis. In an ex vivo rat
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model, Hattar et al. used isolated rat lungs to investigate the pathogenicity of anti-PR3
antibodies (44). Rat lungs were perfused with human neutrophils primed with TNF and
monoclonal anti-PR3 antibodies. This induced marked weight gain in the lungs due to
increased capillary permeability and edema, but no overt vasculitis in the lungs. Again, this
is an interesting model, but more studies are required to understand the underlying
mechanisms and their relevane to human ANCA disease.
As mentioned earlier, antibodies to LAMP-2 have been reported to occur in high frequency
in patients with active PR-ANCA and MPO-ANCA disease (2,3). Kain et al. also reported
evidence that anti-LAMP-2 antibodies are pathogenic in rats (3). Anti-LAMP-2 antibodies
caused pauci-immune necrotizing glomerulonephritis when injected into rats. As discussed
below, cross reactive antibodies induced by immunization with a bacterial protein that has
homology to LAMP-2 also caused disease in rats. These observations are extremely
important because they rats the possibility that antibodies to LAMP-2 are as important if not
more important than antibodies to MPO or PR3 in the pathogenesis of ANCA disease.
However, no other laboratory has yet reported confirmation of either the frequency of anti-
LAMP-2 antibodies in patients or the pathogenicity of these antibodies in animal models.
Origin of the ANCA autoimmune response
So far in this review, the focus had been on the pathogenesis of disease in patients who have
circulating ANCA. Another important issue is the origin and persistence of the autoimmune
response that leads to the pathogenic events. Two mechanisms that have been proposed for
the origin of the ANCA autoimmune response are molecular mimicry of the autoantigen by
a bacterial peptide (3) and induction of autoimmunity through an immune response to the
complementary peptide of the autoantigen that secondarily results in antibodies against the
autoantigen (45).
Kain et al. have proposed that molecular mimicry of LAMP-2 by a the bacterial adhesin
FimH can induce circulating anti-FimH antibodies that cross react with LAMP-2, which can
cause pauci-immune glomerulonephritis and small vessel vasculitis (3). A LAMP-2 peptide
has 100% homology to FimH. Rats immunized with FimH developed antibodies to rat and
human LAMP-2, and developed pauci-immune necrotizing glomerulonephritis. The authors
thus postulate that infection by fimbriated bacteria bearing FimH induces an immune
response that cross reacts with LAMP-2 resulting in the mediation of pauci-immune
necrotizing glomerulonephritis and vasculitis. This is a paradigm shifting concept that
undoubtedly will result in follow up studies from many laboratories. To date, no
confirmatory reports have been published.
Another novel theory for induction of the ANCA autoimmune response postulates that the
initial immune response is against an epitope that is on anti-sense peptide (complementary
autoantigen peptide) or a mimic of an anti-sense peptide rather than against a sense
autoantigen peptide (Figure 1) (45,46). Patients with PR3-ANCA disease have not only
circulating antibodies against sense PR3 peptides but also a separate set of antibodies against
antisense complementary PR3 peptides (anti-cPR3). Theoretically, an immune response to a
complementary PR3 peptide produces anti-cPR3 antibodies, which in turn cause the
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development of anti-idiotypic antibodies that recognize not only the idiotope on the anti-
cPR3 antibodies but also the portion of the PR3 molecule to which the peptide is
complementary. The cPR3 peptide could arise endogenously from transcription of PR3 anti-
sense, or could be introduced exogenously, for example as a component of an infectious
microorganism that has a peptide that mimics cPR3. Interestingly, several pathogens that are
associated with the development of PR3-ANCA (including Ross river virus, Staphylococcus
aureus and Entamoeba histolytica) have constituent mimics of cPR3 (45).
An interesting outgrowth of the theory of autoantigen complementarity is the identification
of autoantibodies with dual reactivity to plasminogen and complementary PR3 in patients
with ANCA disease (47,48). Further, patients with anti- plasminogen antibodies are at
increased risk for thrombotic complications. Plasminogen has an epitope that also occurs in
cPR3, thus suggesting that thye arise secondary to molecular mimicry (47). Berden at al.
noted that patients with anti-plasminogen antibodies had a greater percentages of glomeruli
with fibrinoid necrosis and cellular crescents, and had more severe renal insufficiency,
suggesting a possible role in the pathogenesis of glomerulonephritis (48).
The development of ANCA can be associated with persistent bacterial or viral infections,
especially bacterial endocarditis (49,50). In this setting, ANCA may not result in the
induction of glomerulonephritis or vasculitis, and appropriate therapy should be directed at
eliminating the infection. Clues that a patient may have an infection associate ANCA are
dual PR3-ANCA and MPO-ANCA positivity, and concurrence of other autoantibodies, such
as anti-cardiolipin antibodies or cryoglobulins (50). Patients with non-pathogenic infection-
associated ANCA may have glomerulonephritis caused by infection-induced immune
complex glomerulonephritis (e.g. cryoglobulinemic glomerulonephritis) even though they
do not have ANCA disease.
Drugs and other environmental factors may induce an ANCA autoimmune response. Silica
is a risk factor for ANCA disease (51,52). ANCA disease can be caused by drugs, including
propylthiouracil, hydralazine, D-penicillamine, allopurinol, minocycline and anti-TNF
agents (7,8,53). Visavachaipan recently reviewed their experience seven patients with
Graves' disease who received propylthiouracil and developed ANCA disease (53).
Proteinuria ranged from 0.49–2.9 gram per day. Mean serum creatinine was 2.05 mg/dl with
creatinine clearance of 44 +/− 35 ml/min. Renal remission occurred in all patients after
propylthiouracil was withdrawn and steroids administered.
Regulation of the ANCA autoimmune response
Once an ANCA autoimmune response develops, regulation of the response probably is
critical in whether or not it will be pathogenic. In fact, Cui et al. have presented evidence
that PR3 and MPO ‘natural autoantibodies’ are present in most if not all health individuals
(54). If true, the development of pathogenic ANCA may be the result of Dysregulation of
non-pathogenic natural ANCA rather than the development of a totally new autoimmune
capability (54,55).
Even if ANCA produced by B-cells are the primary pathogenic factors in cause the acute
lesions of ANCA disease, T cells undoubtedly are involved in regulating the genesis,
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persistence and modulation of the ANCA-producing B cell clones, and in regulating the
innate inflammatory responses to acute ANCA injury. A number of recent articles address
these issues (56,
Morgan et al. have demonstrated that patients with Wegener’s granulomatosis demonstrated
abnormalities in the number and function of regulatory T cells and this is most pronounced
in patients with the most active disease (57). In addition, patients with active ANCA disease
who had increased circulating CD4(+) Foxp3(+) cells had a more rapid disease remission.
Chavele et al studied MPO-specific T cell reactivity and regulation during disease remission
and concluded that MPO-specific T cell frequencies are regulated during disease remission
(58). They also noted that FoxP3 levels were diminished in patients compared with controls.
This same group also studied serum IL-17A and IL-23, and the frequency of IL-17-
producing autoantigen-specific T cells in patients with ANCA disease (59). Serum IL-17A
levels were significantly elevated in acute disease compared to healthy controls. Patients
with elevated levels of IL-23 compared to those with low IL-23 had more active disease and
higher ANCA titers. The authors conclude that the Th17 axis is important in the modulation
of ANCA disease. Futher, Lamprecht et al have proposed that modulation of the T-cell
responses in tissue, including Th1 and Th17 responses and dysfunctional regulatory T cells,
could be responsible for the distinctive aggressive granulomatous inflammation of
Wegener’s granulomatosis (60). In line with this study, Wilde et al. have emphasized the
importance of evaluating not only circulating T cells but also tisuue T cells, especially at
sites of injury (61).
To date, there has not been extensive study of the role of T cells in animal models of ANCA
disease. One recent study uses a mouse model of autoimmune glomerulonephritis that
results from apparent synergy between anti-GBM and anti-MPO antibodies (62,63). In this
model, anti-MPO CD4+ T cells appear to act with macrophages to amplify glomerular
injury (62). Using this model, Gan et al. also observed that mice deficient in the Th17
effector cytokine IL-17A were nearly completely protected from developing
glomerulonephritis (62).
Thus, there is evidence that T cells are involved in both the genesis and regulation of the
ANCA autoimmune response, as well as effector events in ANCA disease.
Conclusions
Clinical, in vitro experimental and animal model data support a direct pathogenic role for
ANCA in the pathogenesis of ANCA disease (Figure 1). In vitro evidence indicates that
ANCA IgG can activate neutrophils and monocytes through Fc receptor and Fab’2 binding
resulting in adhesion to endothelial cells and release of cytotoxic factors. In vivo animal
model evidence indicates that ANCA can cause renal and systemic pauci-immune
necrotizing vasculitis that closely resembles human ANCA-associated vasculitis. This
evidence is better for anti-MPO than for anti-PR3 antibodies. T cells appear to play
important roles in the genesis of the autoimmune response, as well as in the orchestration of
tissue injury. The origin and pathogenesis of ANCA disease involves interplay between
multiple environmental, genetic and biological processes that initiate the pathogenic
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autoimmune response, cause the acute lesions, and lead to chronic progression of lesions if
therapy is not fully effective.
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• Clinical, in vitro experimental and animal model data support a direct
pathogenic role for ANCA in the pathogenesis of ANCA disease.
• Neutrophil cytokine priming, antigen presentation cofactors, NETS (neutrophil
extracellular traps), Fc receptor engagement, alternative pathway complement
activation, and multiple signaling pathways are involved in neutrophil
pathogenic activation by ANCA.
• Induction and persistence of the ANCA autoimmune response may involve
multiple mechanisms including environmental stimuli (e.g. silica, drugs, and
microbial pathogens), dysregulation of granule protein gene expression,
autoantigen mimicry, autoantigen complementary (antisense) peptides, and
aberrant T cell regulation.
• Novel treatment strategies can target any of these mechanisms that induce and
sustain the autoimmune ANCA response, or that mediate the pathogenic events
induced by ANCA.
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Figure 1. Immunogenesis and pathogenesis of ANCA disease
Diagram of putative events in the pathogenesis of ANCA disease based on in vitro and in
vivo experimental observations. In the upper left, the theory of autoimmunity induced by an
immune response to a complementary peptide is depicted. The lower left proposes that T
cell regulation is disturbed to allow persistence and progression of autoimmunity. In the
upper right, the aberrant increased production of ANCA antigens by epigenetic
dysregulation of gene expression is illustrated. Once ANCA antibodies are present along
with neutrophils with increased antigens, the sequence of pathogenic events illustrated in the
lower right can occur, i.e. cytokines or other priming factors induce neutrophils to express
more ANCA antigens at the cell surface where they are available for binding to ANCA,
which activates neutrophils by both Fc receptor engagement and Fab’2 binding. Factors
released by neutrophils activate the alternative complement pathway, which generates
factors that amplify recruitment and activation of neutrophils. Activated neutrophils release
toxic factors that cause inflammatory injury to endothelial cells and vessel walls.
(Reproduced with permission of J.C. Jennette)
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